News | Women's Health | August 20, 2020

Single-dose radiotherapy replaces need for extra hospital visits, with benefits for patient safety and well-being

Single-dose radiotherapy replaces need for extra hospital visits, with benefits for patient safety and well-being

Getty Images


August 20, 2020— For most women with early breast cancer, a single dose of targeted radiotherapy during surgery is just as effective as conventional radiotherapy, which requires several visits to hospital after surgery.

This combination of targeted radiotherapy (restricted to the area around the tumour) given immediately after surgery is called targeted intraoperative radiotherapy. Conventional radiotherapy involves repeat doses to the whole breast over several days after surgery.

The findings, published by The BMJ today, show that intraoperative radiotherapy is associated with around an 80% chance of avoiding a full course of conventional radiotherapy, fewer side effects and no difference in survival or likelihood of the cancer returning.

An international team of researchers set out to compare the long term effects of targeted intraoperative radiotherapy (TARGIT-IORT) with conventional whole breast external beam radiotherapy (EBRT) for women with early breast cancer.

Results from an earlier report of single-dose targeted intraoperative radiotherapy were promising, but doctors have been waiting for longer term results before adopting the procedure more widely.

The new findings are based on 2,298 women, aged 45 or older, who were eligible for breast conservation surgery (lumpectomy) at 32 centres in 10 countries in the UK, Europe, Australia, USA and Canada.

Between March 2000, and June 2012, 1,140 women were randomised to receive targeted intraoperative radiotherapy (TARGIT-IORT) and 1,158 received external beam radiotherapy (EBRT).

TARGIT-IORT was given as a single dose immediately after surgery as part of the same operation and under the same anaesthetic, while EBRT was given as a standard daily dose for 3-6 weeks after surgery.

The long term results show that TARGIT-IORT was no worse than EBRT. After five years of monitoring, the local recurrence risk was 2.11% for TARGIT-IORT compared with 0.95% for EBRT. This difference of 1.16% is not considered clinically significant.

In the first five years after surgery, there were 13 additional local recurrences (24 out of 1,140 vs 11 out of 1,158) but 14 fewer deaths (42 out of 1,140 vs 56 out of 1,158) with TARGIT-IORT compared with EBRT.

Over a longer follow-up period (average 8.6 years, maximum 18.9 years) there were no statistically significant differences in local recurrence-free survival (167 vs 147 events), mastectomy-free survival (170 vs 175 events), overall survival (110 vs 131 events) and breast cancer deaths (65 vs 57 events).

Deaths from other causes were significantly lower (45 vs 74 events) with TARGIT-IORT compared with EBRT. The major risk factors for such deaths (age and body mass index) were well matched between the groups.

The researchers point to some study limitations, such as possible overdiagnosis of non-invasive local recurrence affecting the results, and not collecting all the background risk factors for deaths from non breast cancer causes. However strengths included the randomised design, a large sample size with a long duration and high level of complete follow up, suggesting that the results are reliable and robust.

As such, the researchers say that for the large proportion of early breast cancer patients "risk adapted immediate single-dose TARGIT-IORT during lumpectomy is an effective alternative to EBRT, with comparable long-term efficacy for cancer control, and lower non-breast-cancer mortality."

Single-dose TARGIT-IORT during lumpectomy "should be accessible to healthcare providers and discussed with patients when surgery for breast cancer is being planned," they conclude.

For more information: www.bmj.com

Related Content

News | Mammography

October 19, 2021 — If Black women begin mammography screening every other year starting at age 40, breast cancer deaths ...

Time October 19, 2021
arrow
News | Radiation Therapy

October 19, 2021 — RAD Technology Medical Systems (RAD) announced that it will be exhibiting at the 2021 American ...

Time October 19, 2021
arrow
News | Ultrasound Imaging

October 15, 2021 — NeuroLogica Corp., the U.S. healthcare subsidiary of Samsung, introduces the V8; a high-end ...

Time October 15, 2021
arrow
News | Ultrasound Women's Health

October 14, 2021 — In a first-in-world clinical trial, researchers at Sunnybrook Health Sciences Centre in Toronto ...

Time October 14, 2021
arrow
News | Breast Imaging

October 14, 2021 — Delphinus Medical Technologies, Inc. announced that the U.S. Food and Drug Administration (FDA) has ...

Time October 14, 2021
arrow
News | Women's Health

October 11, 2021 — Electrical engineering professor Magda El-Shenawee’s effort to develop a more accurate and less ...

Time October 11, 2021
arrow
News | Lung Imaging

October 11, 2021 — According to ARRS’ American Journal of Roentgenology (AJR), percutaneous image-guided microwave and ...

Time October 11, 2021
arrow
News | Quality Assurance (QA)

October 11, 2021 — To maintain safety in radiation therapy (RT), every machine performance and patient delivery ...

Time October 11, 2021
arrow
News | Women's Health

October 8, 2021 — An analysis of nearly 200,000 patients who received mammograms between 2006 and 2015 across three U.S ...

Time October 08, 2021
arrow
News | MRI Breast

October 7, 2021 — An automated system that uses artificial intelligence (AI) can quickly and accurately sift through ...

Time October 07, 2021
arrow
Subscribe Now